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In the aquaticenvironment, diet is animportant route ofexposure forthe commoncontaminant
and procarcinogen benzo(a)pyrene (BaP). Dietary organisms var'yin their BaP content and in
contaminated areas often contain other xenobiotics including cytochrome P4501A inducers.
This study eamined the effect ofdose and previous dietary exposure to the inducer 3-naph-
thoflavone (BNF) upon the intestinal metabolism of BaP and the sptemic bioavailability of
BaP-derivedproducts in catfish. BaP was administered at 2 and 20 pM into in situ-isolated per-
flsedintestines ofcontrol andBNF-pretreatedcatfish. The intestine formed an arrayofmetabo-
lites in all treatments including potentially hazardous metabolites such as BaP-7,8 and 9,10
dihydrodiols and 6-methy-BaP. BNF treatment disproportionally increased the contribution of
BaP-7,8 and 9,10 dihydrodiols relative to the contributions ofother metabolites. A greater per-
centage ofmetabolites was evident as conjugates in 2 pM controls, whereas a greaterpercentage
of unconjugated metabolites was evident for 20 pM controls and BNF treatments of both
dosages. BNF pretreatment and thehigher20pM BaP dose resultedingreaterbioavailabilit4
with 2.6-5.5-fold and 3.0-6.3-fold s in temicallyavhlable BaPproducts, respectively.
Metabolites represented 10.2-23.1% of the increased bioavilability with BNF treatment, sag-
gesting that mechanisms, in addition to induced metabolism, may be operative. These results
indicate that intestnal bioavailability, level ofbiotransformation, and the metabolic profile of
BaP-derived products entering the bloed from the intestine may be altered by dose and dietary
BNF pretreatment. Key wordk: activation, benzo(a)pyrene; bioavailability, biotransformation,
catfish, eimination, insitupreparation, intestine. Environ HealthPerspect106:155-166 (1998).
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Polynuclear aromatic hydrocarbons (PAHs)
are frequently found as contaminants in
impacted aquatic environments. These
compounds have been associated with areas
that demonstrate a high tumor prevalence
in wild fish populations (1-3). The carcino-
genicity of PAHs is a well-known conse-
quence of their metabolic activation (4).
Among the various PAHs, the model com-
pound benzo(a)pyrene (BaP) has received
the most attention in fish species, with a
primary focus on hepatic metabolism and
adduct formation (5,6). BaP has been
shown experimentally to be carcinogenic to
fish following both waterborne (7) and oral
exposures (8).
The hydrophobicity and environmental
partitioning (9) of BaP, as well as its accu-
mulation in infaunal invertebrates (10,11),
suggest that the diet may be an important
route of exposure for aquatic species.
Studies examining various levels in the
aquatic food chain have demonstrated not
only the presence ofBaP in diet and tissues
but the biotransformation of BaP by lower
organisms and the subsequent food chain
transfer of BaP molar equivalents (Meq) to
higher organisms (12-14). (BaP molar
equivalent is defined here as BaP and BaP-
derived metabolites compositely quantified
by radioactivity and placed on an equal
molar basis using BaP's specific activity.)
Dietary BaP may also undergo bio-
transformation by the intestine ofthe con-
sumer before entering the systemic circula-
tion (15). Intestines offish are capable ofa
wide variety of biotransformation reac-
tions, some of which respond to dietary
cytochrome P4501A (CYPIA) inducers
(16). Dietary induction studies in both
flounder (17) and catfish (16) indicate that
under conditions of low inducer concen-
trations, select biotransformation activities
in the intestine may equal or even exceed
corresponding hepatic activities. Such
induction effects may potentially alter the
degree and pathway of metabolism.
Similarly, in vitro BaP studies with floun-
der intestinal homogenates suggest that the
biotransformation pathways and products
formed in the intestine may be altered by
the BaP dose (17). BaP may be activated or
alternatively detoxified by metabolically
favored pathways. These findings suggest
that the balance between toxification and
detoxification on first-pass metabolism
through the intestine may depend on dose
and previous exposure history.
Objectives ofthe present study were to
examine the intestinal metabolism and
bioavailability of BaP in context of the
products formed under varying conditions
of dose and previous exposure history.
These goals were addressed using an in situ
isolated perfused intestinal model (catfish).
BaP dosages used were based on Km deter-
minations of relevant biotransformation
enzymes in the intestine. Dietary pretreat-
ment was accomplished using the CYPIA
inducer j-naphthoflavone (BNF) at con-
centrations in the diet that would induce
the intestine but not the liver.
Materials and Methods
Channel catfish (1,639 ± 300 g) were
obtained from the Louisiana State
University (LSU) Aquaculture Research
Station, Baton Rouge, Louisiana. Fish for
all treatment groups were maintained under
flow through conditions in dechlorinated
tap water (pH 8.10 ± 0.33; temperature
21.0 ± 1.1°C; total hardness 25.7 ± 7.2 mg
CaCO3/l; alkalinity 170.3 ± 18.2 mg/l) on
a 12-hr light photoperiod. Fish were accli-
matized at least 4 weeks to experimental
conditions before use. All fish were held
and treated in accordance with National
Institutes ofHeath guidelines.
Virgin Silvercup trout chow (Murray
Elevators, Murray, UT) was fed to fish
before experimental treatment. On initia-
tion ofexperimental treatment, control fish
were maintained on trout chow coated with
corn oil (100 pl corn oil/100 g chow),
whereas fish to be induced were fed 1 mg
BNF/100 pl corn oil/100 g chow. Both
dietary groups were maintained on appro-
priate experimental diets at 30 g feed/
kg/day for 14 days before surgical manipu-
lation. Fish were fasted 24 hr before surgery
and in situexperimentation.
Intestinal microsomes were prepared
from control and BNF-exposed catfish for
use in in vitro studies of BaP positional
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metabolism and monooxygenase Km and
Vm determinations. Catfish were immo-
bilized in ice water and sacrificed by sever-
ing the spinal cord (n = 4/treatment).
Intestines were removed, rinsed thoroughly
with ice-cold buffer 1 [0.25 M sucrose, 5
mM EDTA, 0.05M Tris-Cl, pH 7.4, 0.2
mM phenylmethyl sulfonyl fluoride
(PMSF)] to remove contents, and cut
open; mucosal cells were then removed by
scraping with a scalpel. The mucosa was
placed in 10 ml buffer 1 and the cells were
sedimented at 2,000 x g, weighed, and
homogenized in 4 vol buffer 1. Washed
microsomal fractions were prepared by dif-
ferential centrifugation using the procedure
described byJames and Little (18).
[3H]-BaP for enzymatic assays and
other standards was purchased from
Chemsyn (a function ofthe NCI Chemical
Carcinogen Repository; Bethesda MD).
Before use, BaP was purified by neutral
alumina column chromatography (Biorad,
Melville, NY) with stepwise elution by
hexane:toluene mixtures 98:2, 95:5, 90:10,
80:20, 50;50, and 0:100 (19,20). In vitro
positional metabolism ofpurified [3H]-BaP
by intestinal microsomes was determined
by radiochemical HPLC assay of all BaP
metabolites (18). A fluorescence assay of
phenolic BaP metabolites [aryl hydrocar-
bon hydroxylase (AHH)] was used to
determine the Km and BaP monooxygenase
activities (21). Km studies incorporated BaP
concentrations ranging from 0.5 to 10 riM.
Intestinal monooxygenase activities were
also determined by assay of ethoxyre-
sorufin-O-deethylase (EROD) activity
(22). Ethoxyresorufin was prepared from
ethyl iodide and resorufin as described pre-
viously (23) and purified by thin-layer
chromatography (TLC) on silica gel plates.
The formation of resorufin was monitored
in a fluorescence spectrophotometer for 30
min. Cuvettes contained 0.1 M Hepes
buffer, pH 7.6, 1% bovine serum albumin,
2 pM ethoxyresorufin, microsomes (1 mg),
and 2 mM NADPH (added last) in a final
volume of3.0 ml.
In situ protocols. A total of 31 catfish
were prepared for an isolated perfused intesti-
nal segment. Two dosages of [3H]-BaP
(based on the K, determined in the in vitro
studies and environmentally relevant) in a
semipurified micellevehidewereexamined in
a variety of combinations with control or
BNF-induced fish. The [3H]-BaP, as the
nonspecifically tritiated product (45-80
Ci/mmol; Amersham Corporation, Arlington
Heights, IL), was introduced either into the
intestinal lumen or into the blood perfusing
the isolated segment. Six combinations of
experimental parameters were examined:
low BaP dose (2 pM)/non-induced/luminal
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(n = 5); lowBaP dose (2 pM)/induced/lumi-
nal (n = 4); high BaP dose (20 jsM)/nonin-
duced/luminal (n = 4); high BaP dose (20
PM)/induced/luminal (n = 5); low BaP dose
(2 jiM)/noninduced/blood (n = 7); and low
BaP dose (2 pM)/induced/blood (n= 6).
Surgicalprocedures. Catfish of either
sex were anesthetized with buffered
(NaHCO3;) tricane methane sulfonate
(Argent Chemical Company, Redmond,
WA) at induction and maintenance doses
of 106 and 86 mg/l, respectively. On
induction, individual catfish were adminis-
tered 1.5 ml anticoagulant (75 mM sodium
citrate:42 mM citric acid:136 mM dex-
trose) and transferred to an aquatic surgery
table.
The intestine was exposed by a longitu-
dinal ventral midline incision. A ventral
loop of proximal intestine starting 10 cm
caudad to the pylorus and extending abo-
rally approximately 20 cm was used for the
preparation (Fig. 1). The afferent (supply)
vessel, a branch of the coeliacomesenteric
artery, and the corresponding efferent
(drainage) vessel perfusing the prospective
intestinal segment as well as potential col-
lateral vessels were identified and isolated,
and suture (00 silk) was placed loosely
around each. Once ligatures were in place,
blood was drawn from the caudal vein into
a syringe containing citrate anticoagulant.
The syringe, with a total of 10 ml blood
and 1 ml oxygen (as determined by prelim-
inary blood gas studies), was placed on an
orbital mixer that provided gentle agitation
for the cells.
The isolated afferent vessel was cannu-
lated using anticoagulant-filled PE-50
(polyethylene) tubing. Once secured in
place, the line was cleared, attached to a
syringe pump mounted on a rocking plat-
form, and a blood flow rate of0.1 ml/ min
was established. After cannulation of the
efferent vessel with PE-60 tubing, the liga-
tures looselyplaced around collateral vessels
were rapidlytied off. Efferent bloodvolume
was measured to ensure that blood output
equaled input so as to verify that the infu-
sion and drainage were for the isolated seg-
ment. The preparation was transiently
blanchedwith a small amount ofanticoagu-
lant in saline through the afferent cannula.
Throughout blanching, the course was
examined to ensure that the afferent cannu-
lation supplied the intestinal segment
before collection in the efferent cannula; to
determine the efficiency or completeness of
the intestinal segment perfusion; and to
demarcate the length of intestine perfused
in the soon-to-be isolated intestinal segment
preparation. Immediately after blanching,
the region of perfusion was noted and
blood flow reestablished. Ligatures were
then preplaced slightly in from the perfu-
sion margin on the intestine to mark the
isolated segment.
Dosepreparation andintroduction. The
carrier vehicle for intraluminal [3H]-BaP
dosing was a semipurified micellar solution.
The semipurified micellar solution was for-
mulated fresh daily from 2.5 mM
monooleoyl-rac-glycerol, 10 mM sodium
taurocholate, 2.5 mM myristic acid (14:0),
2.5 mMpalmiticacid (16:0), 2.5 mM stearic
acid (18:0), 2.5 mM linoleic acid (18:2), and
0.9% saline. Micelles were formulated in 1
ml saline with the aid of sonication. [3H]-
BaP and nonradiolabeled BaP dosages were
formulated at the experimentally determined
A_ o b 1E
Figure 1. Diagrammatic representation ofthe catfish in situ isolated perfused intestine(ventralview). Letters
indicate the following structures: A, isolated segment of intestine; B, efferent cannula; C, afferent cannula;
D, proximal ligature and border of isolated intestine; E, distal ligature and border of isolated intestine; F,
venous return; G, branch ofcoeliacomesenteric artery; H, spleen; 1, ligatures on collateral vessels.
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monooxygenase Km (2 pM) and 10 Km (20
pM). Purified [3H]-BaP (370-640 pCi) in
hexane and the balance ofthe dose as nonla-
beled BaP in hexane were added to a conical
tube containing saline (3 ml). N2 gas was
used to evaporate the solvent until only a
surface film ofhexane remained. The micel-
lar mixture was introduced below the surface
film. Initially the tube was gently mixed
while the remaining hexane was evaporated,
which allowed the bulk ofthe BaP to parti-
tion into the micelles. Once this was accom-
plished, more rigorous mixing dissolved the
film until an essentially clear solution
remained. Micelles were stable well beyond
the experimental period (>24 hr).
At the time of dosing, the ligature
around the distal extent ofthe perfused iso-
lated intestinal segment was tied off. A
small sample of micelle preinfusate was
then collected for verification ofBaP purity
at time of analysis. The needle of the dos-
ing syringe was inserted through the gut
wall and the tip of the needle extended in
the gut lumen for 2 cm beyond the proxi-
mal ligature. This ligature was then tight-
ened over the needle allowing injection of
the micellar solution and BaP dose into a
nonperforated isolated intestinal segment.
The injected dose was gently massaged
throughout the entire segment, the timer
started, and the room lights turned off to
minimize photolysis ofBaP.
In situ intestinal preparations in select
experiments were dosed with [3H]-BaP via
the perfusion blood. [3H]-BaP in an
ethanol carrier was added directly to blood
so that the BaP dose delivered during the
timed perfusion was the same as that in the
corresponding luminal study (2 pM). Once
[3H]-BaP was added to the blood, the carri-
er vehicle was evaporated and blood was
throughly mixed and loaded into a syringe
for perfusion. A micelle solution ofidentical
composition (except for BaP) and volume
as that used in the luminal studies was
placed in the lumen of the intestinal seg-
ment as a collection medium.
Sample collection. Throughout the
course ofthe 60-min perfusion, the intestine
was moistened with saline (as needed), blood
flow was checked every 10 min, and the iso-
lated segment was gently massaged every 5
min. Whole blood collected compositely
over the 60-min perfusion was sampled at
each flowcheck to ensure proper sample rep-
resentation. At the end of the perfusion,
samples ofliver, kidney, and anestheticwater
were taken for radioactivity analysis to check
the isolated preparation's perfusion integrity.
(In intact isolated preparations, no radioac-
tivity should be present in the samples.) The
isolated ligated intestinal segment was
removed intact and the length measured
under standardized conditions. Postinfusate
was collected by draining the intestinal seg-
ment, volumes were recorded, and aliquots
taken for liquid scintillation counting and
metabolite analysis. Once drained, the
intestinal segment was cut open along the
entire length, copiously washed with saline,
and blotted dry. The mucosal surface was
examined grossly for viability and then
scraped with a glass slide. Mucosal tissue was
mixed and aliquots were taken for liquid
scintillation counting (approximately 100
mg) and metabolite analysis. Preinfusate,
blood, liver, kidney, water, intestinal
mucosa, and postinfusate were processed for
liquid scintillation counting, as described
below. Samples for metabolite determination
(preinfusate, postinfusate, intestinal mucosa,
and blood) were placed under nitrogen,
wrapped in foil, and frozen at -20°C for up
to 1 month until analysis.
Radioassay procedures. Tissue and
postinfusate samples (approximately 100
mg) were digested in TS-1 (0.5 ml) tissue
solubilizer (Research Products International,
Mount Prospect, IL) for 24 hr at 500C. After
cooling, the samples were neutralized with
18 pi glacial acetic acid and counted in 4.5
Table 1. Percent recovery, binding, and decomposition of BaP and metabolite standards through the
analytical procedurea
Compound Tissue Eluted Bound Breakdown
BaP Blood 99.6 0.4 0.4
Mucosa 99.8 0.2 2.0
3-0H-BaP Blood 94.7 5.3 60 (to diones
Mucosa 98.1 1.9 50 (to diones
9-0H-BaP Blood 95.3 4.7 14.4
Mucosa 98.2 1.8 22.1
BaP-7,8-diol Blood 97.7 2.3 11.0
Mucosa 98.3 1.7 7.9
BaP-9-sulfate Blood 98.2 1.8 9.8
Mucosa 96.0 4.0 4.5
BaP-9-glucuronide Blood 84.4 15.6 2.8
Mucosa 96.6 3.4 0.5
Abbreviations: BaP, benzo(a)pyrene; OH-BaP, hydroxybenzola)-pyrene; diol,dihydrodiol.
8Each radiolabeled standard was added to blood or mucosa at a concentration similar to those found in samples and immediately added to
Cl, packing material foranalysis, as described in Methods.
ml scintillant (Ultima Gold, Packard,
Downers Grove, IL). Radioisotope content
was determined in water, preinfusate, and
HPLC fractions following direct addition of
the sample to scintillant. Radioactivity ofall
samples was corrected for counting efficiency
(-50%) and background.
Analysis. Blood, mucosal cell, and
postinfusate medium samples from the
[3H]-BaP-incubated in situ intestinal prepa-
ration were extracted by matrix solid phase
dispersion, as described byJames et al. (20).
Briefly, samples ofmucosal cells, 0.2-0.5 g,
were added to 2 g prewashed, air-dried
octadecylsilane-coated silica beads (C18)'
30-70 pm, (Alltech Associates, Deerfield,
IL). The mixture was gently blended with a
glass pestle to produce an evenly mixed,
semidry material. This material, packed in a
column, was eluted sequentially with 16 ml
heptane and then with 8 ml each toluene,
ethyl acetate, methanol, and water. Solvent
eluents were collected in separate vials. After
solvent elution, the packing material was
extruded from the column, weighed, and
mixed well. Five separate 0.1-g samples were
then added to 18 ml scintillation cocktail
and assayed for radioactivity. Aliquots of
each solvent eluent were counted and the
percentage of radioactivity in each fraction
calculated. The heptane, toluene, ethyl
acetate, and methanol fractions were dried
separately under nitrogen, taken up in 0.25
ml 55% methanol, and filtered through a
0.45-pm centrifuge filter; the solutions were
analyzed by HPLC. Selected aqueous frac-
tions were hydrolyzed before analysis.
Similar procedures were used for blood and
postinfusate except that 0.2-1-ml samples of
postinfusate and 3-6-ml samples of blood
were used. Where sample size was greater
than 0.5 ml, the amount ofpacking material
mixed with the sample and the volume of
eluent used were increased proportionally.
The percentages of recovery, binding, and
decomposition were determined by adding
standards to mucosa, blood, and postin-
fusate and following the above procedure
(Table 1).
The evaporatedandreconstitutedheptane
samples were analyzed for BaP by isocratic
reverse-phase HPLC with an octadecylsilane
(C18) column (4.5 x 50 mm precolumn with
4.5 x 250 mm column) and methanol as the
mobile phase. The flow rate was 0.7 ml/min
and the eluent was passed through UV-VIS
(ultravioletvisable; Beckman model 332 set at
280 nm; Beckman Instruments, Palo Alto,
CA), fluorescence (Shimadzu model RF 535
set atex375, em435; Shimadzu Instruments,
Columbia, MD), and radiochemical
(Packard/Radiomatic Flo-one beta set for
[3H]; Packard Instrument Company,
Meriden, Cl) detectors. The evaporated and
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reconstituted toluene, ethyl acetate, and
methanol fractions were analyzed for BaP
metabolites using a modification ofthe gradi-
ent system described by Salhab et al. (24).
The column and detectors used were as for
the isocratic separation, but the column was
preequilibrated with starting mobile phase,
55% methanol:45% water, foratleast 30 min
before sample injection. After sample injec-
tion, the mobile phase was held at 55%
methanol for 1 min. The amount of
methanol was then increased by linear gradi-
ent to 86.5% MeOH over 30 min, held at
86.5% MeOH for 14 min, increased to
100% MeOH over 2 min, and held at 100%
MeOH for 24 min. The column was then
returned to the starting conditions. The
retention times of BaP metabolite standards
used in this system have been published else-
where (20) except for BaP-3-, 7-, and 9-glu-
curonides, which eluted at 5.4, 5.8, and 5.6
min, respectively. Samples ofdried methanol
extracts and ofthe aqueous phase were incu-
bated overnight at room temperature with I-
glucuronidase or sulfatase, as described previ-
ously (25).
Statistical comparisons were performed
with a 2-factor analysis ofvariance. To model
the simultaneous effects ofpretreatment and
dose, statistical analyses of the experimental
data were performed using the SAS (26) gen-
eral linear models procedure. Pretreatment
and dose level were modeled as separate main
effects. A cross-products term was induded to
assess potential effect modification (interac-
tion). In no instance did the interaction term
have a significant impact on comparison of
the main effects; therefore, the reported analy-
ses areofthe maineffects only. Outcome vari-
ables were the concentration ofmetabolites in
blood and mucosa, the total metabolites
found in postinfusate, and the postinfusate
fluid volume. Where appropriate, a Student's
t-testwas usedforothercomparisons.
Results
Low monooxygenase activity was evident in
intestinal microsomes from control catfish.
HPLC analysis of the BaP metabolites
formed from microsomal incubations
Table 2. In vitro positional metabolism of BaP in
intestinal mucosal microsomes from control catfish
Product(pmol)
Metabolite formed/min/mg protein
Triols and tetrols 0.43
9,10-Diol 0.26
7,8-Diol 0.23
Diones 0.85
7 and 9-OH-BaP 0.28
3-OH-BaP 1.28
Total activity 3.34
Abbreviations: BaP, benzo(alpyrene; OH-BaP, hydroxy
benzo(a)-pyrene; diol, dihydrodiol.
Table3. Intestinal monooxygenase activities in catfish fed vehicle-treated chow or chow containing BNF,
10 mg/kg diet, for 2 weeks
AHH EROD
Vmax
Treatment Km(pM) pmol/min/mg pmol/min/mg protein
Vehicle-treated chow 1.83 ± 1.06 12.5 ± 10.3 1.86± 0.92
BNF-treated chow 1.44 ± 0.46 70.2± 24.5* 11.5 ± 4.03*
Abbreviations: AHH, aryl hydrocarbon hydroxylase; BaP, benzola)pyrene; BNF, 3-naphthoflavone; EROD, ethoxyre-
sorufin O-deethylase activity.
*Significantly higherthan control,p<0.05.
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Figure 2. Scatter graphs showing the concentrations of benzo(a)pyrene (BaP) and metabolites in the
blood from in situ-isolated perfused catfish intestine. The fourtreatment groups were control infused
with 2 pM BaP;P-naphthoflavone (BNF)-treated infused with 2 pM BaP; control infused with 20 pM BaP;
and BNF-treated infused with 20 pM BaP. Statistical analysis showed significant effects of both BNF
treatment and concentration infused for parent BaP and the unconjugated metabolites.
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showed that the major metabolites were 3-
OH-, 7-OH-, and 9-OH-BaP, BaP-diones,
BaP-7,8-dihydrodiol (BaP-7,8-D), and
BaP-9,10-dihydrodiol (BaP-9,10-D) (Table
2). 3-OH-BaP accounted for 25-35% of
the primary BaP metabolites formed by
intestinal microsomes. The apparent Km for
BaP (AHH) in intestinal microsomes from
fish fed vehicle-treated chow alone was 1.83
± 1.06gM. Intestinal microsomes from cat-
fish treated with BNF demonstrated a sig-
nificant 5.6-fold increase in the AHH V
value (Table 3). The intestinal microsomes
from BNF-treated catfish also had a 6.2-
fold higher EROD activity (Table 3). BaP
substrate concentrations of 2 pM, close to
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the control Km (1.83), and 20 PiM (10 Ki)
were used for dosage considerations in the
insitu intestinal preparations.
Total BaP Meq entering the systemic cir-
culation in the in situ intestinal preparation
varied with dose and with BNF treatment of
the fish. A 10-fold increase in BaP dose
administered resulted in a significant
3.0-6.3-fold increase insystemically available
(blood) BaP Meq (Fig. 2). BNF pretreat-
ment resulted in significant 5.5- and 2.6-fold
increases in systemically available BaP Meq
for the 2 and 20 IM doses, respectively (Fig.
2). Analysis ofradioactivity entering the sys-
temic circulation for each ofthe in situtreat-
ments indicated that the increase in BaP
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Figure 3. Scattergraphsshowing the concentrations ofbenzo(a)pyrene (BaP) and metabolites in the
mucosa from insitu-isolated perfused catfish intestine. The fourtreatment groups were control infused
with 2 pM BaP;P-naphthoflavone (BNF)-treated infused with 2pM BaP; control infused with 20pM BaP;
and BNF-treated infused with 20 pM BaP. Statistical analysis showed no significant effects of BNFtreat-
ment onthe concentrations of BaP ormetabolites in mucosa. The concentration of BaP infused signifi-
cantly affected the concentration of BaP and each group of metabolites in mucosa.
Meq with BNF pretreatment consisted of
significant increases in parent BaP and
unconjugated metabolites (Fig. 2).
Metabolites accounted for 10.2 and 23.1%
ofthe increased BaP Meq in blood ofBNF-
treated animals for the 2 and 20 jM doses,
respectively.
Intestinal mucosa demonstrated signifi-
cant differences in total BaP Meq with dose.
A 10-fold increase in luminal dose resulted
in 8.1- and 5.4-fold increases in total mucos-
al BaP Meq concentrations for control and
BNF-treated animals, respectively. Increased
BaP Meq with dose was represented by
increases in BaP, unconjugated metabolites,
and conjugates (Fig. 3). Pretreatment with
BNF resulted in a composite 1.8-fold
increase in mucosal BaP Meq at the 2 pM
dose and a 1.2-fold increase at the 20 pM
dose. These changes were also represented by
BaP and unconjugated and conjugated
metabolites.
Awide varietyofprimary and secondary
metabolites of BaP were formed and trans-
ported to the systemic circulation in situ.
Unconjugated oxidative products included
hydroxy-BaP, BaP-diones, BaP-7,8-D, BaP-
9,10-D, BaP-7,8,9,10 tetrols, and other
minor unconjugated metabolites (Table 4).
The in situ oxidative profile was similar to
those demonstrated in in vitro studies, with
the exception that hydroxylated metabolites
were quantitatively much less important.
Conjugates that predictably represented a
significant fraction in situconsisted primari-
ly of glutathione, sulfate, and glucuronide
conjugates. The percentage of total recov-
ered radioactivity as metabolites in the in
situ preps ranged between 8.3 and 17.3%
for blood and 5.3 and 10.2% for the
mucosa. For all treatments the mucosa con-
tained much higher absolute BaP and
metabolite concentrations than blood
(Tables 4 and 5). With the exception of
BaP diones at the mucosal 20 jiM dose and
hydroxy BaP at the blood 20 pM dose,
BNF treatment resulted in greater concen-
trations ofmetabolites in both the intestinal
mucosa and the perfusing blood. This
increase was significant for six of the nine
reported metabolite classifications in blood
and for two of nine in mucosa. When
metabolite concentrations were ranked
based on their relative abundance among
the major metabolites reported, several pat-
terns emerge (greatest abundance = highest
rank). Conjugate concentrations were con-
sistently the highest ranked category in both
blood and mucosa in both control and
BNF-treated animals. BaP diones as a
group were the second highest category for
all treatments in the blood and the controls
at both concentrations for the mucosa.
Interestingly, the relative amounts ofdiones
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dropped precipitously relative to those of
other metabolites in the BNF treatments
for both concentrations in mucosa. In terms
of ranking among metabolites, relatively
more OH-BaP was present in the mucosa
than in the blood.
BaP-7,8-D and 9,10-D were evident in
blood, mucosa, and postinfusate for both
control and BNF treatments at the 2 and
20 pM dosages (Tables 4-6). BaP-7,8-D
accounted for 1.8-9.7, 4.2-11.2, and
0.98-2.4% of all metabolites for blood,
mucosa, and postinfusate, respectively. In a
similar comparison, BaP-9,10-D represent-
ed 3.9-13.9, 4.0-16.5, and 0.5-2.6% of
all metabolites. Within a category (control
or BNF treated), changing the dose from 2
to 20 pM resulted in increased concentra-
tions ofBaP-7,8-D and 9,10-D in all sam-
ples. BNF treatment resulted in increased
BaP-7,8-D and 9,10-D concentrations in
blood and mucosa. BaP-7,8-D percentages
in BNF-pretreated animals were from 1.3-
to 5.4- and 1.5- to 2.7-fold higher than
those for controls for blood and mucosa,
respectively. Similarly, BNF treatment
resulted in BaP-9,10-D percentages that
were 3.1- to 3.2 (blood)- and 1.8- to 3.6
(mucosa)-fold higher than those for con-
trols. As a result, BNF treatment elevated
the ranking of BaP-9,10-D in blood and
both BaP-7,8-D and 9,10-D in mucosa rel-
ative to those for other metabolites.
The total BaP Meq, metabolite abun-
dance, and postinfusate volumes recovered
from the intestinal lumen following the 1-
hr in situ exposure are shown in Table 6.
Postinfusate volumes recovered were signif-
icantly lower with BNF treatment at both
the 2 and 20 pM BaP dosages. Average
total BaP Meq concentrations in the recov-
ered postinfusate were 744, 1,265, 9,791,
and 8,484 pmol for the 2 pM control, 2
pM BNF-treated, 20 pM control, and 20
pM BNF-treated groups, respectively.
When the BaP Meq levels were examined
on a per-unit basis, the BNF groups consis-
tently demonstrated higher values. BaP
Meq ofpostinfusate, mucosa, and blood on
per-unit bases indicate that within a treat-
ment, the BaP Meq of mucosa was 1,855,
667, 1,404, and 546 times higher than that
ofthe postinfusate for the 2 pM control, 2
pM BNF, 20 pM control, and 20 pM
BNF treatments, respectively. Similarly,
the BaP Meq of mucosa was 20,622,
6,620, 26,427, and 11,902 times higher
than that of the blood for the same treat-
ments. For both the mucosa-postinfusate
and mucosa-blood comparisons, substan-
tial reductions in the concentration differ-
ential within a dose treatment were evident
with BNF treatment. Metabolites com-
prised 12.9, 9.4, 9.5, and 9.0% ofthe total
radioactivity in the postinfusate for the 2
pM control, 2 pM BNF, 20 pM control,
and 20 pM BNF treatments, respectively.
BNF treatments resulted in elevated aver-
age metabolite concentrations for seven
metabolite classifications at 2 pM and four
metabolite classifications at 20 pM.
The metabolite profiles of radioactivity
in postperfusate blood and the intestinal
mucosa following [3H]-BaP exposure via
infused blood are shown in Table 7. BaP
and a wide variety ofmetabolites were evi-
dent in both the blood and mucosa. The
major constituent for both the blood and
mucosa was the parent BaP. BNF increased
the total metabolites twofold in the blood
and 1.8-fold in the mucosa; however, total
BaP Meq (including BaP) concentrations
were not significantly different between
treatments. Significantly greater amounts of
OH-BaP, BaP-diones, BaP-7,8-D, and
BaP-9,10-D were evident in the blood and
BaP-7,8-D in the mucosa upon induction
than in controls. On an equivalent unit
basis, the mucosa had three orders ofmag-
nitude higher BaP Meq concentrations than
the postinfusate blood. After the BaP par-
ent, the next largest categories in the blood
were BaP diones, conjugates, unidentified
metabolites, and OH-BaP, respectively, for
both control and BNF treatments. The
mucosa demonstrated a somewhat different
profile from the blood, with the BaP-diones
much less prevalent and OH-BaP, BaP-
9,10-D, and conjugates more prevalent
than the other metabolites.
6-Methyl-BaP, identified as apotentially
hazardous BaP metabolite in mammalian
systems, was found in blood, mucosa, and
postinfusate ofthe catfish in situpreparation
Table 4. Composition of radioactivity in the blood of control and BNF-induced catfish following exposure
to 2 or 20 pM [3H]-BaP in the lumen
Statistical
Metabolite (pmol/ml blood)a comparisonsb
2pM 2pM 20 pM 20pM BNF Dose
Control BNF-treated Control BNF-treated effect, effect,
Metabolite (n= 5) (n=4) (n=4) (n=5) p-value p-value
BaP 17.6 + 13.8 99.4 ± 58.9 118.3 + 58.2 274.2 +62.1 <0.001 <0.001
6-Methyl-BaP 0.041 ± 0.03 0.30 ± 0.33 0.20 +0.20 0.25 +0.13 0.122 0.530
OH-BaP ND 0.45 ± 0.42 0.80 ± 1.11 0.79 + 0.61 0.471 0.073
BaP-diones 0.47 0.55 1.94 1.06 3.38 4.78 15.8 19.0 0.184 0.113
BaP-7,8-diol 0.05 ± 0.07 1.18 ± 1.21 0.62 ± 0.70 4.39 ± 1.48 <0.001 0.005
BaP-9,10-diol 0.12 ± 0.17 1.68 ± 1.68 0.42 ± 0.60 7.05 ± 3.43 0.003 0.024
BaP-7,8,9,10-tetrol 0.01 + 0.02 0.08 ± 0.07 0.06 ± 0.11 0.37 ± 0.32 0.049 0.079
Other unconjugated
metabolites 0.20 + 0.33 1.65 ± 0.94 1.58 ± 1.94 11.9 ± 8.36 0.026 0.028
Conjugates 1.90 ± 3.06 4.81 ± 4.54 3.69 ± 2.23 17.0 ± 13.0 0.044 0.078
Unidentifiedc 0.13 ± 0.12 1.23 ± 0.78 0.98 ± 0.91 6.63 ± 4.13 0.013 0.020
Abbreviations: BaP, benzo(a)pyrene; BNF, f-naphthoflavone; diol, dihydrodiol; ND, notdetectable (<0.02 pmol/ml).
"Values shown are mean ± standard deviation.
bStatistical comparisons were performed with 2-factor analysis ofvariance; significant at p<0.05.
cThe unidentified fraction was radioactivity not eluted from theCl, matrix and is likelyto include break-down products from glutathione and
glucuronide conjugates of BaP metabolites (seetext).
Table 5. Composition of radioactivity in the mucosa of control and BNF-induced catfish following in situ
exposure to 2 or 20 pM [3Hl-BaP
Statistical
Metabolite (pmol/mg mucosa)a comparisonsb
2pM 2 pM 20 pM 20 pM BNF Dose
Control BNF-treated Control BNF-treated effect, effect,
Metabolite (n= 5) (n= 4) (n= 3) (n= 5) p-value p-value
BaP 395 183 663 146 3243±650 3562 1816 0.568 <0.001
6-Methyl BaP 0.69 0.32 1.04 0.38 3.40± 1.83 6.72 5.19 0.265 0.011
OH-BaP 3.15 1.79 14.0 13.0 14.8 ± 13.7 51.3 34.2 0.048 0.028
BaP-diones 4.28 ± 3.99 6.67 ± 4.06 58.5 ± 41.1 29.7 ± 11.2 0.223 0.001
BaP-7,8-diol 1.08 ± 0.66 8.04 ± 5.59 12.0 ± 8.2 40.9 ± 30.7 0.075 0.022
BaP-9,10-diol 1.03 ± 0.81 10.4 ± 5.67 16.5 ± 3.75 67.2 ± 62.4 0.127 0.048
BaP-7,8,9,10-tetrol 0.25 ± 0.31 0.53 ± 0.52 0.06 ± 0.10 0.74 ± 0.62 0.058 0.929
Other unconjugated 2.13 2.62 4.43 3.97 14.6 ± 11.2 27.0 12.5 0.128 <0.001
metabolites
Conjugates 13.3 ± 15.6 26.4 ± 14.2 60.7 ± 12.6 183 ± 122 0.100 0.010
Unidentified 2.27 ± 1.33 11.70 ± 6.41 12.7 ± 8.27 58.9 ± 31.4 0.018 0.008
Abbreviations: BaP,benzola)pyrene; BNF, ,-naphthoflavone; diol, dihydrodiol.
"Values shown are mean ± standard deviation.
bStatistical comparisons were performed with 2-factor analysis ofvariance; significant atp<0.05.
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for all treatments (Tables 4-7). Compared
to other reported metabolites, 6-methyl-
BaP was found in small quantities in the
blood and mucosa and proportionally larg-
er amounts in the postinfusate. BNF pre-
treatment did provide a significant increase
in 6-methyl-BaP for those fish exposed
through the blood (Table 7). Generally,
more 6-methyl-BaP was evident with
increasing dose for the mucosa and postin-
fusate.
Discussion
Intestinal CYPIA activity has been exam-
ined in several fish species under control
and induced conditions. Control AHH
activities of intestinal microsomes from
vendace, perch, roach (27), scup (28),
toadfish (15), and spot (29) range from 0.4
to 40 pmol/min/mg protein. EROD activi-
ties of 56 and 65 pmol/min/mg have been
reported for control spot (29) and mummi-
chog (30), respectively. Studies examining
induction have demonstrated varying
responses depending on the species, induc-
er, and dietary regime (15,29-31). Spot
exposed to 3-methylcholanthrene (3-MC)
(10 mg/kg food for 5 days) had a 17.1-fold
increase in AHH activity, whereas the same
species administered BaP in the diet (16
mg/kg for 4 days at 2%/day) had an 8.5-
fold increase (29,31). Toadfish adminis-
tered BaP in the diet (10 mg/kg food at
5% body weight every third day) experi-
enced a 9.7-fold increase in AHH
activity(15). AHH activities of induced
animals in these studies ranged from 320 to
720 pmol/min/mg protein (15,29,31).
Similarly, induced EROD activities were
36- and 10-fold higher for spot exposed to
3-MC (29) and mummichog exposed to
BNF (BNF 250 mg/kg food) (30), with
activities ranging from 667 to 2,018
pmol/min/mg protein. BNF administra-
tion in the present study resulted in an
increase in AHH activity from 12.5 to 70.2
pmol/min/mg protein and EROD activity
from 1.86 to 11.5 pmol/min/mg. CYPIA
Table 6. Composition of radioactivity in intestinal lumen postinfusate mediumafollowing exposure of con-
trol or BNF-induced catfish for 1 hrto 2 or20 pM [3HI-BaP
Statistical
Metabolite (pmol in postinfusate)a comparisonsb
2 pM 2pM 20pM 20pM BNF Dose
Control BNF-treated Control BNF-treated effect, effect,
Metabolite (n= 5) (n=4) (n=4) (n=4) p-value p-value
Volume after 1 hr(ml) 3.26 1.6 1.13 0.26 4.00 1.80 1.15 ±0.44 <0.001 0.510
BaP 619 475 1128 243 8724±2338 7571± 6570 0.853 <0.001
6-Methyl-BaP 2.51 ± 2.13 4.98 ± 1.90 21.24 ± 13.72 21.69 ± 26.76 0.843 0.027
OH-BaP 1.75 ± 2.36 5.21 ± 4.19 47.0 ± 57.3 22.1 ± 30.9 0.481 0.054
BaP-diones 42.6 ± 47.4 42.1 ± 29.7 549 ± 565 255 ± 125 0.275 0.015
BaP-7,8-diol 0.90 1.10 2.84 1.04 18.84 ± 28.6 10.6 ± 16.2 0.721 0.114
BaP-9,10-diol 0.91 ± 1.85 2.98 ± 1.16 4.55 ± 3.43 11.2 ± 12.4 0.199 0.087
BaP-7,8,9,10-tetrol 0.76 ± 1.28 2.79 ± 2.11 3.67 ± 6.22 8.66 ± 9.62 0.227 0.136
Other unconjugated 5.59 ± 7.26 9.13 ± 2.90 33.3 ± 26.7 76.7 ± 60.8 0.184 0.013
metabolites
Conjugates 36.5 ± 24.6 46.7 ± 20.8 235 ± 132 346 ± 158 0.246 <0.001
Unidentified 33.2 ± 54.7 20.1 ± 4.6 154 ± 142 161 ± 87 0.943 0.005
Abbreviations: BaP, benzo(a)pyrene; BNF,P-naphthofIavone; diol, dihydrodiol.
'The total volume left inthe intestine afterthe perfusion differed significantly between control and BNFtreatment groups butwas not
dependent on initial BaP concentration; initially, 4 ml was infused into each intestinal preparation.
bStatistical comparisons were performed with 2-factor analysis ofvariance; significant atp<O.05.
Table 7. Composition of radioactivity in blood and mucosa of control and BNF-induced catfish following
exposure to 2 pM [3H]-BaP inthe blood
Blood(pmol/ml) Mucosa (pmol/mg)
Control BNF-treated Control BNF-treated
Metabolite (n=7) (n=6) (n=7) (n=6)
BaP 123±47 157±38 109±53 114±61
6-methyl-BaP 0.17 0.07 0.35 ± 0.14* 0.11 ±0.04 0.11 ±0.05
OH-BaP 0.31 ± 0.23 1.06 ± 0.51* 1.47 ± 1.20 2.38 ± 2.30
BaP-diones 2.97 ± 1.41 6.42 ± 2.53* 0.60± 0.45 1.11 ± 0.64
BaP-7,8-diol 0.14 0.14 0.82 ± 0.49* 0.84 0.62 2.03 1.16*
BaP-9,10-diol 0.08 0.08 0.61 ± 0.55* 1.24 0.94 3.13 1.28
BaP-7,8,9,10-tetrol 0.06 ± 0.08 0.08 ± 0.09 0.57 ± 0.58 0.66± 0.27
Other unconjugated metabolites 0.31 ± 0.22 0.42± 0.25 0.20± 0.21 0.27 ± 0.22
Conjugates 1.95 ± 1.36 3.33 ± 1.16 3.56 ± 3.79 6.26 ± 3.95
Unidentified 1.19 0.59 1.66 ± 0.54 1.17 ± 0.42 1.63 0.96
Abbreviations: BaP, benzo(a)pyrene; BNF, P-naphthoflavone; diol, dihydrodiol.
*Significantly higherthan control, p<0.05.
intestinal activities ofcatfish were consider-
ably lower than those of the mummichog
(30), spot (29,31), and toadfish (15) for
both the respective controls and induced
treatments. For those other studies and
species for which only controls were exam-
ined, the catfish control activities were of
comparable magnitude. The higher CYP1A
activities in the mummichog, spot, and
toadfish relative to that in the catfish may
be due to some level of induction in these
field-collected fish or to inherently higher
basal activities in those species. In addition,
for induced animals, BNF has been shown
in vitro to be an inhibitor for catfish
intestinal EROD, AHH, UDP-glucurono-
syl-transferase (UGT) and PAPS-sulfo-
transferase (ST) activities. The concentra-
tions that inhibit 50% (IC50) for EROD,
AHH, ST, and UGT were c[emonstrated to
be 0.078 ± 0.022, 2.2 ± 0.09, 48.0 ± 3.0,
and 46.9 ± 15.1 pM, respectively (16). The
catfish intestinal biotransformation
enzymes appear to be highly sensitive to
inhibition by BNF. This is not true for all
fish species, as dietary BNF dosages much
higher than those used here have resulted
in significant intestinal CYPIA induction
(30).
Intestinal microsomes from catfish
maintained on the control diet produced
several major metabolites, including 3-
OH-BaP, other benzo-ring phenols, and a
variety of dihydrodiols. This group of
metabolites was similar to those produced
in the liver of other fish species such as
sheepshead minnow, killifish (32), starry
flounder, English sole (33), and scup (34).
Intestinal microsomes of control catfish
demonstrated a 18.7-fold lower total BaP
metabolite yield than that reported for the
liver (16). The percentages of individual
metabolites, however, were quite similar for
3-OH-BaP (intestine, 38%; liver, 38.5%),
7-OH and 9-OH BaP (intestine, 8.4%;
liver, 11.1%), and BaP-7,8-D (intestine,
6.9%; liver, 11.7%). Substantial differences
were observed for the diones (intestine
25.4%; liver 10.5%). BaP-7,8-D, a precur-
sor to the major putative carcinogen, was
formed to a significantly greater degree as
in other fish species and in liver micro-
somes than by their mammalian counter-
parts (35-37). Although large quantitative
differences exist for total BaP metabolite
production between hepatic and intestinal
microsomes of controls, induction studies
utilizing BNF under identical exposure
conditions as used presently have demon-
strated nearly identical AHH activities for
the two organs (16). The importance ofthe
intestine relative to the liver in biotransfor-
mation of dietary BaP may be linked to the
level ofdietary induction ofthe intestine.
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Within individual treatments of the in
situ studies, mucosal BaP Meq concentra-
tions were 546-1,855 times higher than
those for the postinfusate micelle solution.
Similarly, mucosal BaP Meq concentrations
were 6,620-26,427 times higher than the
blood. The differences for mucosal-blood
comparisons were greatest for control treat-
ments at either the 2 or 20 IpM dosage
regimes (mucosa was 20,622-26,427-fold
higher than blood). BaP Meq concentra-
tions in the mucosa, postinfusate, and blood
all increased with BNF preexposure. The
relative increases, however, were muchlarger
for the blood and postinfusate than for the
mucosa. Effectively in face of absolute
increases, BNF pretreatment lowered
mucosal BaP Meq concentrations relative to
either the intestinal lumen or the blood.
These findings may be related to several
events coinciding with BNF preexposure: 1)
an increase in metabolite formation; 2) an
apparent reduction in the recoverable
micelle volume in the intestinal lumen over
the duration ofthe in situperfusion; and 3)
a relatively greater bioavailability of BaP
Meq to the systemic circulation.
BNF, in many fish species, is known to
be an effective inducer of CYPIA activity
(38-40) aswell as amodest inducerofphase
2 activities such as glucuronosyl transferase
(41) and glutathione-S-transferase (16,30).
Metabolism may act upon intestinal
bioavailability by providing substrates for
specific transporters such as themultispecific
organic anion transporter (42,43) or by
metabolizing the lipophiic BaP parent to a
metabolite with a polarity more favorably
suited for absorption. Previous studies in
which 3-OH-BaP was administered into the
intestinal lumen of the catfish have shown
that primarily the conjugates of3-OH-BaP
were transported from the mucosa to the
blood (44). Similarly, sulfate and glu-
curonide conjugates of 9-OH-BaP have
been shown to be readily absorbed intact
from the intestinal lumen into the systemic
circulation of the catfish (44). Given the
similarity in lipid solubility of 3-OH-BaP
and BaP (compared to that in conjugates)
and what perhaps may be a ready transport
of conjugates, increased metabolism may
facilitate movement oflipophilic BaP Meq
from the lumen to the circulation. Although
the systemic availability of BaP Meq
increased 2.6-5.5-fold with BNF pretreat-
ment, the increase in metabolites available to
the blood represented only 10.2-23.1%
(depending on dose) of the increased Meq
entering the systemic circulation. This infor-
mation suggests that although metabolism
was likely to have an effect, it probably is
not the sole determining factor in the
changes in bioavailability.
Perhaps BNF exposure alters cellular
structure and/or integrity thereby affecting
bioavailabiity. BNF has been shown to elic-
it structural and biochemical changes in fish
(45,46) as well as to inhibit metabolism
(phase 1 and 2) (16,4X. Brown bullheads
exposed to BNF at high concentrations
(500 mg/kg diet) in the diet exhibited
reduced body weights, physical deformities,
and epithelial hyperplasia on body surfaces.
Similar effects such as reduced bodyweights
and gill and fin lesions have been observed
with other Ah receptor agonists (TCDD,
for example) in black bullheads (48). On a
molecular basis, BNF (100 mg/kg) has been
shown to alter hepatic phospholipid metab-
olism in the rainbow trout, with a 34%
increase in microsomal phospholipid con,
tent within 24 hr of BNF administration
(46). The BNF dosages used in the current
study were 50 times lower than those
exhibiting overt toxicity (45), 333 times
lower than doses used in lipid studies (46),
and much lower than those commonly used
in hepatic induction studies (49). Although
histology was not performed and signs of
gross toxicity were not evident in in situ
prepared fish, the selective reduction in per-
fusate volumes with dietary BNF pretreat-
ment indicates that the catfish gastrointesti-
nal tract was different in some manner
because of BNF administration. Reduction
in postinfusate volumes over the duration
of the perfusion by an unknown mecha-
nism may have increased the BaP concen-
tration gradient from the intestinal lumen
to the systemic circulation. This increase in
the concentration gradient, a solvent drag
phenomenon, or a permeability change may
have increased the net influx ofBaP Meq.
A third possible explanation for the
increase in BaP Meq bioavailability with
BNF exposure mayrelate to the induction of
transporter function. Although a specific
transporter has not been identified as being a
factor in these studies, it is known that BNF
induces the function of at least one trans-
porter in the intestine ofcatfish (50). This
transporter, P-glycoprotein, is known to
transport BaP in mammalian liver cells (51).
It is not known if metabolites of BaP are
similarlytransported.
When insituintestinal studycomparisons
are made between metabolism ofcatfish in
the current study and toadfish fed BaP (a
weaker inducer than BNF) at 10 mg/kg food
at 5% ofbody weight every 3 days, we find
that approximately 8.3-17.3% ofBaP in the
bloodwas metabolized in the catfish prepara-
tion compared to 62-90% for the toadfish
(15). In vitro AHH activities for pretreated
control andinduced toadfishhadvaluesof33
and 320 pmol/min/mg microsomal protein,
respectively. These values are nearly threefold
higherthan controls and4.6-fold higher than
induced activities, as demonstrated for catfish
in the current study. Such apparent differ-
ences in levels of biotransformation may
account for the large differences in amounts
ofmetabolites produced in the in situ intesti-
nal preparation between the two studies. In
addition to enzymaticactivities, several exper-
imental differences may contribute to the
contrasting in situ studies. These differences
include species (catfish vs. toadfish), species
source (hatchery vs. field), inducer selection
(BNF vs. BaP), length ofperfused intestinal
segment (isolated segment vs. whole intes-
tine), circulatoryperfusion method (dosedvs.
open), BaP carrier vehicle (micelle vs. oil),
and the method of metabolite analysis
(HPLC vs. differential extraction). In vivo
studies with rats (52) and fish (53) also indi-
cate extensive metabolism ofdietary BaP by
the intestine. Further study is necessary to
determine if differences are associated with
thespecies ortheexperimental protocols.
In the in situpreparations, high concen-
trations ofBaP-7,8 and 9,10-D were found
in the intestinal mucosa relative to those in
the blood and micelle postinfusate. These
dihydrodiols appear to arise from the rela-
tively robust activity of catfish mucosal
epoxide hydrolase on the respective BaP-
oxides (16). It is likely that the higher BaP-
7,8 and 9,10-D concentrations present in
the intestinal mucosa are primarily a result
ofbuildup at the site ofproduction, as oral-
ly administered BaP-7,8-D has been shown
to be readily transferred from the fish intes-
tine (54). Quantitatively, the proportions
and absolute concentrations ofBaP-7,8 and
9,10-D were greater for BNF-pretreated
animals. BNF pretreatment resulted in
1.3-5.4-fold and 1.5-2.7-fold increases in
BaP-7,8-D percentages for blood and
mucosa, respectively. Comparisons for BaP-
9,10-D demonstrated similar differences,
with blood and mucosa attaining 3.1-3.2-
fold and 1.8-3.6-fold higher percentages
with BNF treatment. Although direct
intestinal or insitucomparisons are unavail-
able, incubation ofBaP with hepatic micro-
somes from induced and uninduced scup
(55), southern flounder (32), starry floun-
der, and English sole (33) resulted in elevat-
ed dihydrodiol concentrations and either
small increases, no change, or decreases in
the percentage oftotal metabolites as dihy-
drodiols following in vivo induction. In
most fish studies, induction with CYPIA
inducers results in increased concentrations
ofdihydrodiols as well as other metabolites.
Studies with catfish hepatic microsomes, as
well as studies here with the intestine, indi-
cate not only indiscriminate increases in
metabolites but some selectivity in BaP-7,8-
D and 9,10-D formation upon induction.
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Proportional increases in the dihydrodiol
contribution with induction have been
demonstrated in a variety of mammalian
studies and are due to induction ofepoxide
hydrolase as well as CYP1A (56). In the cat-
fish intestine the elevated dihydrodiol con-
centrations with BNF pretreatment appear
to be due to increased CYPIA activities in
face ofhigh but noninduced levels ofepox-
ide hydrolase activity (16). Importantly, the
catfish intestine responds to dietary BNF by
producing greater proportions ofpotentially
hazardous BaP metabolites that may be
transported by the systemic circulation to
distant sites. Classic toxicokinetic studies
with intravenous BaP and BaP-7,8-D in the
winter flounder indicate higher volumes of
distribution (Vd) and clearance rates with
BaP-7,8-D (54). Clearly these features offer
contrasting risks because the increased
polarity of BaP-7,8-D facilitates elimina-
tion, whereas a larger volume of distribu-
tion poses greater access of a more proxi-
mate carcinogen (BaP-7,8-D) to susceptable
macromolecules.
6-Methyl-BaP and 6-OH-methyl-BaP
(data not included) were shown to be
formed in the catfish in situintestinal prepa-
ration. To the authors' knowledge this is the
first time these metabolites have been tenta-
tively identified in a fish species. 6-Methyl-
BaP has been demonstrated in mammals to
arise in vivofrom the methylation ofBaP by
methyl transferase (57), whereas 6-OH-
methyl-BaP results from a P-450-mediated
hydroxylation ofthe methylated metabolite.
6-Methyl-BaP and 6-OH-methyl-BaP as
well as the sulfate, phosphate, and acetate
esters of6-OH-methyl-BaP, when given to
animals, have been shown to form protein
and DNA adducts through the 6-methylene
group (58). These adducts may arise from
an SN2 (substitution nucleophilic biomolec-
ular) reaction ofthe ester of6-OH-methyl-
BaP with cellular nucleophiles or by the sul-
fation of6-OH-methyl-BaP and loss ofthe
sulfate anion possibly to form a reactive car-
bocation (58,59). Further investigation will
be necessary before the importance ofthese
potential pathways of BaP activation are
known forthe fish intestine.
Diones were major contributors to the
total metabolites in the in situ intestinal
preparation as they were for the microsomal
positional metabolism. Intestinal mucosa
contained much higher concentrations of
diones on a per-unit basis than either the
blood or postinfusate. In general, the
amount of diones increased from the 2 1M
to the 20 pM dose for both control and
BNF comparisons. BNF pretreatment result-
ed in increased dione concentrations for both
the 2 IM and 20 pM concentrations ofthe
blood and the 2 pM concentration in the
mucosa. For the 20 pM treatment, dione
concentrations in mucosa demonstrated a
large drop with BNF pretreatment. Diones
constituted a lower percentage of the total
metabolites for BNF treatments than in con-
trols for mucosa and marginally lower in the
blood. This response is in contrast to the rel-
ative increases in percentages ofBaP-7,8 and
BaP 9,10-D on BNF pretreatment. A likely
explanation for these findings is that induc-
tion ofCYPIA by BNF favors formation of
benzo-ring arene oxides, the precursors to
benzo-ringdihydrodiols.
When BaP was administered into the
intestinal lumen ofthe in situ preparations,
between 33.9 and 60.1% (depending on
treatment) ofthe metabolites in the postin-
fusate were diones. This compares to
7.3-32.4% for the mucosa and 16.0-31.4%
for the blood across identical treatments.
For studies where BaP was administered
through the blood, diones accounted for
49.6 and 49.0% of the blood metabolites
for the 2 pM control and BNF treatments,
respectively. The mucosa in these same
treatments contained between 6.9 and 7.5%
oftotal metabolites as diones. Although the
mucosa contained the highest absolute
dione content, it also accounted for the
greatest BaP Meq concentrations and total
net metabolism. Conversely, the postin-
fusate and blood, although not producing
metabolites to the same degree as mucosa,
were represented to a much greater degree
by dione formation. There are interesting
corollaries ofthese observations to the situa-
tion in many invertebrates in which P450
metabolism is low and dione formation is of
greater importance (60). Although compar-
isons with intestinal or in situ preparations
are not available, the percent ofmetabolites
as diones has been reported for hepatic
microsomes from a variety of fish species
(6). Ofthe studies examined, the percent of
diones formed by fish ranged from 3.8 to
28%, with a median value ofapproximately
13%. The percent of metabolites as diones
reported here for the in situ intestinal prepa-
ration generally fell into this range except for
the high values for the postinfusate across all
treatments and the postperfusate blood
(control and BNF pretreated) of the blood
exposure studies. Large-scale air oxidation of
the BaP appears to be an unlikely explana-
tion for the high levels of diones in these
samples because preinfusate handled in an
identical fashion but without exposure to
tissues did not exhibit significant dione pro-
duction. Pathways of xenobiotic oxidation
that characteristically form BaP diones have
been identified with the vasculature and
hematin ofmammals (61). Dione formation
in mammals is thought to occur by the
intermediacy of a BaP cation radical (62)
and 6-OH-BaP (63,64) through a one-elec-
tron oxidation mechanism. This oxidation
may occur with BaP acting as a reducing
cosubstrate for the oxidation ofarachidonic
acid by prostaglandin H synthase (PHS) or
by reactions catalyzed by heme containing
proteins and lipid hydroperoxides. Tissues
with low monooxygenase activity and high
PHS concentrations such as the alimentary
tract and vasculature are favorable sites for
this oxidation route (61). Concentrations of
PHS in fish tissues are unknown; however,
P450 activities generally are lower in thevas-
cular (65-67) and intestinal (16) compart-
ments than in the liver, especially in unin-
duced animals. Predictably, an attempt with
liver microsomes to detect the 6-oxy-BaP
free radical in fish was largely unsuccessful
(6). Non-P450-dependent metabolic routes
and transport differences in the intestine
and the vasculature are plausible explana-
tions for the prominent role of diones in
these selectstudies and samples.
Conjugates represented a major compo-
nent in the blood and intestinal mucosa,
accounting for between 26.5 and 65.0%
and 31.4 and 51.3% of the recoverable
metabolites, respectively. Blood and mucosa
ofcontrols demonstrated greater composite
conjugate concentrations than the unconju-
gated metabolites at the 2 pM dose, where-
as at the 20 pM dose the unconjugated
metabolites attained 1.9-2.0-fold higher
concentrations. BNF treatment, while
increasing absolute concentrations of all
metabolites, appeared to negate these find-
ings, as the unconjugated metabolites pre-
dominated at both the 2 and 20 pM con-
centrations. Both dose and BNF pretreat-
ment appeared to facilitate in absolute
terms the increased production of intesti-
nally derived metabolites. Conjugate con-
centrations, although sensitive to these
mechanisms, demonstrated incongruencies
with the larger response ofthe unconjugat-
ed metabolites. Relative limitations in phase
2 metabolism in face of increased concen-
trations ofphase 1 metabolites may account
for the observed findings. This concept is
supported by previous BNF induction stud-
ies with catfish intestine that have demon-
strated little induction of glutathione-S-
transferase and no induction ofUGT or ST
(16). In addition, BNF treatment also
increases CYP1A production of BaP-7,8-
oxide and BaP-9,10-oxide, which in turn
leads to increased BaP-7,8-D and 9,10-D
formation, as well as 7- and 9-hydroxy BaP
(Fig. 3). The resulting BaP-dihydrodiols are
poorer substrates for glucuronidation than
BaP-phenols (68), which leads to a buildup
of unconjugated dihydrodiols relative to
hydroxy-BaP. Strict dose effects indicate
that such limitations may also be related to
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Figure 4. Metabolic cascade for benzo(a)pyrene (BaP) via the cytochrome P4501A (CYPlA) products BaP-7,8-oxide and BaP-9,1O-oxide.
KmIVmaX as well as availability considera-
tions. Intestinal mucosal homogenates from
flounder administered dietary BNF when
incubated with BaP at 0.5 and 5.0 pM
exhibited greater amounts of BaP conju-
gates, whereas at 50 and 250 pM, conju-
gates fell relative to the polar metabolites
and unmetabolized BaP (17). Asimilar dose
dependence appears to exist here for the in
situintestinal metabolism ofBaP.
The water-soluble fractions and HPLC
peaks eluting before 10 min in the present
study are likely to include a mixture ofsul-
fate, glucuronide, and glutathione conju-
gates of the oxidative metabolites of BaP
(Fig. 4). The large number of potential
conjugates from BaP-phenols, BaP-dihy-
drodiols, and BaP-oxides, in light of their
overlapping physicochemical properties,
made isolation of individual polar conju-
gates difficult based on retention character-
istics. Incubation of radioactivity eluted
from the C18 matrix beads by water and
methanol with 1-glucuronidase or sulfatase
suggested that up to 20% ofthe conjugates
found were a mixture of glucuronides and
sulfates. More than 80% ofthe conjugates
were not hydrolyzed by sulfatase or P-glu-
curonidase, suggesting that these were glu-
tathione conjugates and further metabolites
of glutathione conjugates. Others have
shown that glutathione conjugates were the
major metabolites of orally administered
BaP (0.1-2 mg/kg) excreted in vivo in bile
ofseveral fish species (6,69). In addition to
the water and methanol fractions eluted
from theC18 matrix beads, there is evidence
that a portion of the unidentified radioac-
tivity not eluted from the C18 beads includ-
ed breakdown products ofglucuronide and
glutathione conjugates [Table 1; Tong and
James, unpublished observations; (70)].
Intestinal microflora are thought to be
minimal contributors to the observed find-
ings. There is no evidence that these organ-
isms contain the P450s or conjugative
enzymes involved in BaP oxidation or conju-
gation [Fig. 4; (71-73)]. Microflora, however,
do contain reductive and hydrolytic enzymes.
Degradative reactions such as dehydroxyla-
tion and hydrolysis of glucuronides may
decrease postinfusate metabolite concentra-
tions. This effect is thought to be minimized
because fasting aswell as dearingfecal materi-
alwould beexpected to reduce bacterial num-
bers andtheirmetaboliccontribution (74).
A considerable degree of variation was
evident in all aspects of these studies. Fish
are inherently variable relative to a number
of key biotransformation enzymes (75).
Intestinal studies pose other challenges.
Catfish because of their poikilothermic
nature and feeding behavior show varia-
tions in food consumption and hence in in
vivo intestinal induction. This is problem-
atic because healthwise they do not tolerate
long-term repetitive handling as in gavage
feeding. In addition, variable boundaries
imposed by the circulation in perfusion
studies, the somewhat variable length of
the perfusion segment because of the state
ofrelaxation and contraction ofthe in situ
intestine, the wide scope of available bio-
transformation pathways, and the dynamic
nature (turnover) ofthe mucosal cells con-
taining uptake and biotransformational
sites all contribute to variability.
In summary, the systemic bioavailability
ofBaP molar equivalents from the intestine
was significantly greater with higher BaP
dosages and BNF pretreatment. BNF gener-
ally increased metabolite production; how-
ever, increases in bioavailability could not be
accounted for solely by changes in metabo-
lism. Intestinal formation and systemic
uptake ofpotentially hazardous metabolites
and detoxification products of BaP in the
catfish intestine appear to be related to dose
and BNF pretreatment through an interplay
ofprimary and secondary biotransformation
pathways. Conjugates were proportionally
favored under low-dose uninduced condi-
tions, whereas benzo-ring diols were propor-
tionally more important upon BNF preex-
posure. Clearly the interplay ofdose, exoge-
nous agents, and intestinal function are
important factors in the uptake, disposition,
and riskassociatedwith dietaryBaP.
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